common side effects of trizivir
diarrhea
nausea
nausea
vomiting
comprehensive list of adverse effects
needed effects
abacavir
lamivudine
zidovudine
unwanted side effects
medical attention
following side effects
taking abacavir
lamivudine
zidovudine
check
doctor
abacavir
lamivudine
zidovudine side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
side effects
patients with abacavir hypersensitivity
nausea
vomiting
diarrhea
fever
lethargy
rash
hypersensitivity reactionabacavir
lamivudine
zidovudine
postmarketing reports
sensitization reactions
including anaphylaxis
abacavir
hypersensitivity reactions
including fever
rash
fatigue
nausea
vomiting
diarrhea
abdominal pain
pharyngitis
malaise
achiness
dyspnea
cough
lethargy
headache
myalgia
arthralgia
myolysis
edema
abnormal chest x-ray findings
localized infiltrates
paresthesia
anaphylaxis
hepatitis
liver failure
renal failure
hypotension
sore throat
adult respiratory distress syndrome
respiratory failure
death
lymphadenopathy
mucous membrane lesions
conjunctivitis
mouth ulceration
erythema multiforme
elevated liver function tests
elevated creatine phosphokinase
elevated creatinine
lymphopenia
fatal hypersensitivity reactions
abacavir
such reactions
multi-organ failure
anaphylaxis
first weeks of abacavir therapy
median onset
days
abacavir hypersensitivity reactions
time during therapy
patients with the human leukocyte antigen subtype b *
hla-b *
allele
higher risk of abacavir hypersensitivity reactions
such reactions
patients without the hla-b
allele
abacavir hypersensitivity
patients in clinical trials with abacavir-containing products
patients
hla-b
allele
incidence
suspected abacavir hypersensitivity reactions
clinical trials
hla-b
carriers
abacavir hypersensitivity reactions
following
following key signs/symptoms
fever
rash
gastrointestinal symptoms
including nausea
vomiting
diarrhea
abdominal pain
constitutional symptoms
including
generalized malaise
fatigue
achiness
respiratory symptoms
including dyspnea
cough
pharyngitis
reactions
fever
rash
reactions
fever
rash
signs/symptoms
patients with hypersensitivity reaction
rash
nausea
vomiting
diarrhea
abdominal pain
dyspnea
cough
fever
fatigue/lethargy
malaise
headache
elevated liver function tests
myalgia
other signs/symptoms of hypersensitivity
mouth ulceration
sore throat
adult respiratory distress syndrome
respiratory failure
edema
lymphadenopathy
hypotension
conjunctivitis
anaphylaxis
paresthesia
lymphopenia
hepatitis
liver failure
myolysis
arthralgia
elevated creatine phosphokinase
elevated creatinine
renal failure
abnormal chest x-ray findings
infiltrates
death
symptoms of abacavir hypersensitivity reaction
continued therapy
abacavir
restarting abacavir after a hypersensitivity reaction
severe symptoms within hours
life-threatening hypotension
death
life-threatening reactions
hours
restarting abacavir in patients
reasons
symptoms of hypersensitivity
key symptom of hypersensitivity
nausea
nausea
vomiting
diarrhea
abdominal distension
abdominal discomfort
pain
gaseous symptoms
dyspeptic symptoms
constipationuncommon
dry mouth/hyposalivationfrequency
abdominal crampsabacavir
lamivudine
zidovudine
postmarketing reports
abdominal pain
oral mucosal pigmentation
stomatitis
dyspepsiaabacavir
nausea
vomiting
diarrhea-rare
pancreatitislamivudine
nausea
vomiting
diarrhea
abdominal pain
upper abdominal pain-rare
elevated serum amylase
pancreatitis-frequency
oral ulcerations
lesionszidovudine
nausea-common
vomiting
abdominal pain
diarrhea-uncommon
flatulence-rare
oral mucosa pigmentation
dyspepsia
pancreatitis
pancreatitis
expanded access program for abacavir
malaise
fatigue
temperature regulation disturbance
fever
chills
pain
ear/nose/throat infectionsabacavir
lamivudine
zidovudine
postmarketing reports
weaknessabacavir
fever
lethargy
fatiguelamivudine
fatigue
malaise
fever-frequency
drug-resistant hepatitis b virus
hbv
zidovudine
malaise-uncommon
fever
generalized pain
chills
chest pain
influenza-like syndrome
emergence of lamivudine-resistant hbv
hiv
hbv-coinfected patients
using lamivudine-containing antiretroviral regimens
suspected stevens-johnson syndrome
sjs
toxic epidermal necrolysis
patients
using abacavir
combination with agents
sjs
cases of erythema multiforme
sjs
abacavir hypersensitivity
brownish-black discoloration of nails
months of zidovudine therapy
months if the drug
discoloration
longitudinal streaks
transverse bands
disorders of sweat
sebum
dry skin
skin rashes
pruritusabacavir
lamivudine
zidovudine
postmarketing reports
alopecia
erythema multiforme
stevens-johnson syndrome
urticariaabacavir
rash
systemic symptoms
stevens-johnson syndrome
toxic epidermal necrolysis
erythema multiforme-frequency
sweet
syndromelamivudine
rash
alopeciazidovudine
rash
skin pigmentation
urticaria
sweating-frequency
discoloration
nailbed hyperpigmentation
leukocytoclastic vasculitis
eosinophilia
fever
headache
dizziness
taste impairmentabacavir
lamivudine
zidovudine
postmarketing reports
paresthesia
peripheral neuropathy
seizures
dizzinessabacavir
headachelamivudine
peripheral neuropathy
paresthesiazidovudine
headache-common
dizziness-rare
paresthesia
somnolence
convulsions
disturbance
syncope-frequency
generalized seizures
status epilepticus
vertigo
wernicke
syndrome
elevated alt
abnormal liver function testsabacavir
lamivudine
zidovudine
postmarketing reports
hepatic steatosis
elevated bilirubin
elevated transaminases
posttreatment exacerbations of hepatitis babacavir
frequency
elevated ggtlamivudine
elevated liver enzymes
ast
alt
hepatitis-frequency
hepatic decompensationzidovudine
elevated liver enzyme levels in blood
elevated bilirubin levels in blood-rare
liver disorders
steatosis
frequency
acute hepatic failure
elevated alt
times
upper limit of normal
uln
patients
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
elevated ggt
expanded access program for abacavir
hepatic decompensation
patients
hiv
hepatitis c virus
hcv
receiving combination
antiretroviral therapy for hiv
interferon alfa
ribavirin
severe acute exacerbations of hepatitis
patients with hepatitis b after discontinuation of lamivudine
patient
preexisting hepatitis b
acute hepatic failure weeks
starting zidovudine therapy
neutropenia
wbcsabacavir
lamivudine
zidovudine
postmarketing reports
aplastic anemia
anemia
including
pure red cell aplasia
severe anemias
therapy
lymphadenopathy
thrombocytopenia
splenomegalyabacavir
frequency
agranulocytosislamivudine
neutropenia
anemia
pure red cell aplasiazidovudine
anemia
neutropenia
leukopenia-uncommon
thrombocytopenia
pancytopenia
marrow hypoplasia
pure red cell aplasia-very
aplastic anemia-frequency
hematologic toxicity
including neutropenia
severe anemia
exacerbation of anemia
neutropenia
mm
patients
agranulocytosis
addition of abacavir
multi-drug regimen
neutropenia
anemia
lamivudine
zidovudine
hematologic toxicity
including neutropenia
severe anemia
patients with advanced hiv
disease
anemia
neutropenia
leukopenia
higher doses
mg/day
patients with advanced hiv disease
poor bone marrow reserve at baseline
cd cell
mm
hematological effects
weeks of therapy
incidence of neutropenia
patients with low neutrophil counts
hemoglobin levels
serum vitamin b levels at baseline
exacerbation of anemia
hiv
hcv-coinfected patients
using zidovudine
ribavirin
feeding problems
anorexia/loss of appetite
hypertriglyceridemia
hyperamylasemiafrequency
hyperglycemiaabacavir
lamivudine
zidovudine
postmarketing reports
hyperlactatemia
lactic acidosis
anorexia/decreased appetite
redistribution/accumulation of body fatabacavir
anorexia-frequency
lactic acidosis
hyperlactatemia
redistribution/accumulation of body fatlamivudine
frequency
lactic acidosis
hyperlactatemia
redistribution/accumulation of body fatzidovudine
anorexia-rare
lactic acidosis
hypoxemia
frequency
lactic acidosis
hyperlactatemia
redistribution/accumulation of body fatcombination
antiretroviral therapy
frequency
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
metabolic abnormalities
hypertriglyceridemia
hypercholesterolemia
insulin resistance
hyperglycemia
hyperlactatemia
hypertriglyceridemia
mg/dl
hyperamylasemia
uln
hyperglycemia
mmol/l
patients
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
redistribution/accumulation of body fat
antiretroviral therapy
causality
elevated cpk
uln
patients
myopathy
myositis
pathological changes
hiv
disease
prolonged zidovudine use
zidovudine study
myalgias
elevated cpk
treated patients with a cd cell count
mm
none of the patients with higher cd cell counts
dose reduction
course of myopathy
drug discontinuation
improvement of symptoms
month
muscle biopsy
necrotic fibers
ragged-red fibers
large accumulations of mitochondrial
fibrillar sarcoplasmic inclusions
elevated creatine phosphokinase
cpk
musculoskeletal pain
muscle painabacavir
lamivudine
zidovudine
postmarketing reports
myalgia
arthralgia
muscle weakness
rhabdomyolysislamivudine
arthralgia
muscle disorders-rare
rhabdomyolysiszidovudine
myalgia-uncommon
myopathy-frequency
symptomatic myopathy
myositiscombination
antiretroviral therapy
frequency
osteonecrosis
disorders
depressive disorders
anxietyfrequency
preexisting depressionabacavir
lamivudine
zidovudine
postmarketing reports
insomnia
other sleep disorderslamivudine
insomniazidovudine
anxiety
depression
loss of mental acuity-frequency
confusion
mania
grandiosity
viral respiratory infectionsabacavir
lamivudine
zidovudine
postmarketing reports
abnormal breath sounds/wheezinglamivudine
nasal symptoms
coughzidovudine
dyspnea-rare
cough
frequency
immune reconstitution/reactivation syndrome
autoimmune disorders in the setting of immune reconstitution
graves
disease
polymyositis
guillain-barre syndrome
frequency
renal signs/symptoms
frequency
dysuriazidovudine
urinary frequency
abacavir
lamivudine
zidovudine
postmarketing reports
cardiomyopathy
vasculitisabacavir
postmarketing reports
myocardial infarction
mi
zidovudine
cardiomyopathy
reversible congestive heart failure
vasodilation
observational study
rate of mi in patients on combination
antiretroviral therapy
increased risk of mi with the use of abacavir within the previous months
sponsor-conducted pooled analysis of clinical trials
excess risk of mi in abacavir-treated patients
control subjects
available data from the observational cohort
clinical trials
abacavir
lamivudine
zidovudine
postmarketing reports
gynecomastiazidovudine
gynecomastia
zidovudine
frequency
macular edema
least case of macular edema
zidovudine in a patient with history of anterior uveitis
syphilis
side effects of trizivir
fda
healthcare professional for medical advice
chills
stomach pain
cough
diarrhea
fever
headache
muscle weakness
nausea
numbness
tingling of the face
feet
hands
pain in the joints
pain in the muscles
pale skin
shortness of breath
skin rash
sore throat
swelling of the feet
lower legs
swelling of the feet
lower legs
unusual feeling of discomfort
illness
unusual tiredness
weakness
vomiting
yellow eyes
skin
black, tarry stools
blood in the urine
stools
red spots on the skin
unusual bleeding
bruising
bone pain
loss of appetite
sleeplessness
trouble sleeping